1. Scrip
  2. >>Rare Diseases

BridgeBio’s Hub-And-Spoke Model: An Interview With Cameron Turtle

 
• By Joseph Haas

Since raising $135m in 2017 to address rare, monogenic diseases, BridgeBio has launched or purchased 17 companies and built a pipeline of 30-plus candidates. Scrip checked in as the company nears commercialization.

BridgeBio lab
A researcher works in the lab of one of BridgeBio's portfolio companies • Source: BridgeBio Pharma Inc.

Since its inception in 2015, BridgeBio Pharma, Inc. has employed a hub-and-spoke business model similar to those used by Roivant Sciences Ltd. and Fortress Biotech Inc., putting its expertise and capital-raising prowess to work by simultaneously addressing multiple rare, monogenic diseases with no approved drugs. To date, the company has launched or acquired 17 companies (along with others still in stealth mode) and boasts a pipeline of 30-plus drug candidates, with one just approved and another with an action date in May or June.

In a wide-ranging interview with Cameron Turtle, senior vice president of portfolio management and corporate development, Scrip discussed the progress...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

Liver Injury REMS Delays Agios’s Pyrukynd US FDA Approval In Thalassemia

 
• By Mandy Jackson

Approval in alpha- and beta-thalassemia by a Sept. 7 action date seemed assured, but an FDA review of proposed REMS regarding potential liver injury pushed it back to Dec. 7.

AL-S Pharma’s AP-101 Shows Efficacy In ALS Clinical Trial

 
• By Jessica Merrill

The Phase II study tested AP-101 safety and tolerability as the primary endpoint but showed “clinically meaningful” efficacy in exploratory endpoints.

Zydus Beats Gilead, Ipsen On Cholangitis Primary Endpoint But Pruritus Data Is Key

 
• By Vibha Ravi

Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.

Amylyx’s Late-Stage Drug Fails In PSP, But Focus Remains On Avexitide

 
• By Jessica Merrill

The drug that was once commercialized as Relyvrio for ALS failed to show a benefit in adults with progressive supranuclear palsy.

More from Scrip

Executives On The Move: New CEO At Mitsubishi Tanabe Pharma

Recent moves in the industry include C-suite changes at Mitsubishi Tanabe Pharma and Oculis Holding, plus clock.bio gets a new chief business officer from BioNTech.

Liver Injury REMS Delays Agios’s Pyrukynd US FDA Approval In Thalassemia

 
• By Mandy Jackson

Approval in alpha- and beta-thalassemia by a Sept. 7 action date seemed assured, but an FDA review of proposed REMS regarding potential liver injury pushed it back to Dec. 7.

‘Attenuated’ Survival Benefit In Bemarituzumab Trial Delays Filing Plans

 
• By Alaric DeArment

Amgen and Zai Lab said the final analysis of the FORTITUDE-101 trial showed a decreased magnitude of OS benefit in first-line gastric cancer.